Recent share performance and business snapshot

ADMA Biologics (ADMA) has drawn investor attention after a sharp pullback, with the stock down about 27% over the past month and roughly 49% over the past 3 months from a last close of US$7.93.

Against this weaker recent share performance, the company reports annual revenue of US$509.864 million and net income of US$165.354 million, supported largely by its ADMA BioManufacturing segment and a smaller contribution from Plasma Collection Centers.

That pullback comes after a very strong multi year run, with the stock showing a 3 year total shareholder return of 97.76% and a 5 year total shareholder return of about 3.6x. However, shorter term share price momentum has clearly faded, as the 1 year total shareholder return is down 59.89%.

If ADMA's recent volatility has you reassessing your watchlist, it can be helpful to scan for other healthcare related opportunities through our screener of 35 healthcare AI stocks.

With ADMA trading at US$7.93 alongside an indicated intrinsic discount and a value score of 5, the key question is simple: is this recent weakness a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 62.1% Undervalued

Against the last close of $7.93, the most followed narrative pegs ADMA Biologics at a fair value of $20.93, implying a wide valuation gap built on detailed growth and margin assumptions.

Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF, 134 MUSD, revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029, growth of 21%/year), currently undervalued.

Read the complete narrative. Read the complete narrative.

If you want to see how this valuation case is built, the key ingredients are revenue compounding, ambitious profit margins and a future earnings multiple that assumes meaningful profitability. The tension sits between those growth targets and what the current price implies.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on ambitious revenue, margin and multiple assumptions; any setback in product demand or plasma sourcing could quickly challenge the undervalued case.

Next Steps

With sentiment clearly split between risks and rewards, now is a good time to look through the details yourself, weigh both sides, and review the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If ADMA has sharpened your focus on opportunities, do not stop here. Broaden your search and let a structured approach surface ideas you might otherwise miss.

• Target potential bargains by scanning companies that appear mispriced on quality and valuation using our 46 high quality undervalued stocks.
• Prioritise resilience by reviewing companies with stronger financial footing through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot off-the-radar opportunities before the crowd by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.